<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8384">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02106104</url>
  </required_header>
  <id_info>
    <org_study_id>DC2013RENALIS</org_study_id>
    <secondary_id>U1111-1143-9518</secondary_id>
    <secondary_id>2013-002493-47</secondary_id>
    <secondary_id>NL47157.029.13</secondary_id>
    <nct_id>NCT02106104</nct_id>
  </id_info>
  <brief_title>Renal Effects of DPP-4 Inhibitor Linagliptin in Type 2 Diabetes</brief_title>
  <acronym>RENALIS</acronym>
  <official_title>A Phase 4, Monocenter, Randomized, Double-blind, Comparator-controlled, Parallel-group, Mechanistic Intervention Trial to Assess the Effect of 8-week Treatment With the Dipeptidyl Peptidase-4 Inhibitor (DPP-4i) Linagliptin Versus the Sulfonylurea (SU) Derivative Glimepiride on Renal Physiology and Biomarkers in Metformin-treated Patients With Type 2 Diabetes Mellitus (T2DM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VU University Medical Center</source>
  <oversight_info>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to detail the (mechanisms underlying the) actions of the DPP-4
      inhibitor linagliptin on the renal system in patients with type 2 diabetes mellitus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Based on preclinical and small-sized studies in non-diabetic individuals, incretin-based
      therapies, i.e. glucagon-like peptide (GLP)-1 receptor agonists and dipeptidyl peptidase-4
      inhibitors (DPP-4i), may hold promise in preventing the onset and progression of diabetic
      kidney disease. However, the potential renoprotective effects of these agents, that are
      believed to be effectuated &quot;beyond glucose control&quot;, have not been sufficiently detailed in
      human diabetes.

      Therefore, the present study aims to explore the mechanistic and clinical effects of DPP-4i
      on renal physiology and biomarkers in patients with type 2 diabetes.

      Forty-eight patients with type 2 diabetes will undergo an eight week intervention with
      linagliptin or glimepiride in order to assess changes in the outcome parameters.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Changes from baseline following 8-week treatment with a DPP-4i versus SU derivative on renal hemodynamics, measured as Glomerular Filtration Rate / Effective Renal Plasma Flow (determined by the combined inulin/para-aminohippuric-acid clearance method)</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal tubular function</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal damage, measured by urine biomarkers</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure and Heart Rate</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Body anthropometrics: body weight, height, body mass index, waist circumference</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Body fat content</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Systemic hemodynamic variables (blood pressure, heart rate, stroke volume, cardiac output/-index, total systemic vascular resistance)</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Derived from non-invasive beat-to-beat finger blood pressure measurements</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiac autonomic nervous system function</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Microvascular function</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Arterial stiffness</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Glycemic variables</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Glycated hemoglobin (HbA1c) and fasting glucose</description>
  </other_outcome>
  <other_outcome>
    <measure>Lipid spectrum</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>DPP4- and ACE activity</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Linagliptin (N=24)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Glimepiride (N=24)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin 5 mg QD</intervention_name>
    <description>Linagliptin 5 mg will be taken orally, once daily for 8 weeks</description>
    <arm_group_label>Linagliptin (N=24)</arm_group_label>
    <other_name>Trajenta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glimepiride 1 mg QD</intervention_name>
    <description>Glimepiride 1 mg will be taken orally, once daily for 8 weeks</description>
    <arm_group_label>Glimepiride (N=24)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with type 2 diabetes (HbA1c: 6.5-9.0% DCCT or 48-75 mmol/mol IFCC)

          -  Metformin monotherapy; using a stable dose for at least 3 months prior to inclusion

          -  Both genders (females must be post-menopausal)

          -  Caucasian

          -  Age: 35-70 years

          -  Body Mass Index: 25-40 kg/m2

          -  All patients with previously diagnosed hypertension should use a RAS-interfering
             agent (angiotensin converting enzyme inhibitor/angiotensin II receptor blocker) for
             at least 3 months

        Exclusion Criteria:

          -  Current / chronic use of the following medication: thiazolidinediones, insulin,
             glucocorticoids, immune suppressants, antimicrobial agents or chemotherapeutics.
             Subjects on diuretics will only be excluded when these drugs (e.g.
             hydrochlorothiazide) cannot be stopped for the duration of the study

          -  Chronic use of NSAIDs will not be allowed, unless used as incidental medication (1-2
             tablets) for non-chronic indications. However, no such drugs can be taken within a
             time-frame of 2 weeks prior to renal-testing

          -  Pregnancy

          -  Frequent occurrence of (confirmed) hypoglycemia (plasma glucose &lt;3.9 mmol/L)

          -  Estimated Glomerular Filtration Rate &lt; 60 mL/min/1.73m2 (determined by the
             Modification of Diet in Renal Disease (MDRD) study equation)

          -  Current urinary tract infection and active nephritis

          -  Recent (&lt;6 months) history of cardiovascular disease, including: acute coronary
             syndrome, chronic heart failure (New York Heart Association grade II-IV), stroke,
             transient ischemic neurologic disorder

          -  Current atrial fibrillation

          -  Complaints compatible with or established gastroparesis and/or neurogenic bladder

          -  Active liver disease

          -  History of or actual pancreatic disease

          -  History of or actual malignancy

          -  History of or actual severe mental disease

          -  Substance abuse (alcohol: defined as &gt;4 units/day; smoking/nicotine: defined as daily
             smoking/use)

          -  Allergy to any of the agents used in the study

          -  Inability to understand the study protocol or give informed consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michaela Diamant, MD PhD FRCPE</last_name>
    <role>Principal Investigator</role>
    <affiliation>VU University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marcel H.A. Muskiet, MD</last_name>
    <phone>+31-(0)20-4442780</phone>
    <email>ma.muskiet@vumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>VU University Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcel H.A. Muskiet, MD</last_name>
      <phone>+31-(0)20-4442780</phone>
      <email>ma.muskiet@vumc.nl</email>
    </contact>
    <investigator>
      <last_name>Michaela Diamant, MD PhD FRCPE</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marcel HA Muskiet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 2, 2014</lastchanged_date>
  <firstreceived_date>March 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VU University Medical Center</investigator_affiliation>
    <investigator_full_name>M. Diamant</investigator_full_name>
    <investigator_title>MD PhD FRCPE</investigator_title>
  </responsible_party>
  <keyword>Type 2 diabetes mellitus</keyword>
  <keyword>Diabetic kidney disease</keyword>
  <keyword>Diabetic nephropathy</keyword>
  <keyword>Renoprotection</keyword>
  <keyword>DPP-4 inhibitors</keyword>
  <keyword>Linagliptin</keyword>
  <keyword>SU derivatives</keyword>
  <keyword>Glimepiride</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>BI 1356</mesh_term>
    <mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
